Cardiovascular Diseases Clinical Trial
Official title:
Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children
People infected with HIV are now living longer lives because of the use of highly active antiretroviral therapy (HAART). However, HAART medications have been shown to increase the risk of cardiovascular disease and metabolic dysfunction in adults. More research is needed on the effect of HAART in children. The purpose of this study is to assess cardiovascular risk factors in children infected with HIV who receive HAART medications and to determine the effectiveness of an exercise program on cardiovascular outcomes in these children.
People infected with HIV are now living longer and healthier lives than HIV-infected people
of previous generations because of the widespread use of HAART medications. However, as HIV
infection becomes a more chronic illness, rather than a fatal disease, researchers are
beginning to identify the long-term complications of HIV infection and its treatment. Adults
infected with HIV are increasingly developing the following: hyperlipidemia and
dyslipidemia, both of which are associated with high cholesterol levels; endothelial
dysfunction; insulin resistance; and changes in body composition, including increased
obesity levels and an increase in central body fat. These conditions are all associated with
an increased risk of cardiovascular disease. More research is needed to examine how children
infected with HIV who are receiving HAART may be affected by these conditions. In this
study, researchers will examine children infected with HIV who are receiving HAART (as well
as a control group of children who are not infected with HIV) to evaluate vascular function
and inflammation over time and how they affect body composition, fat redistribution, insulin
resistance, hyperlipidemia, growth, nutrition, bone metabolism, and disease severity. This
study will also evaluate the effectiveness of an exercise program on vascular function and
cardiovascular outcomes in children infected with HIV who are receiving HAART.
There are two parts to this study. In Part 1, children infected with HIV and their siblings
and friends who are not infected with HIV will attend study visits every 6 months for 3
years. At select visits, the following study procedures will occur: medical history review;
physical exam; blood collection; body measurements; questionnaires regarding diet, quality
of life, and activity levels; and an echocardiogram to obtain images of the heart.
In Part 2 of the study, a portion of participants from Part 1 of the study who are infected
with HIV will be randomly assigned to take part in a 12-week exercise program or a control
group. At a baseline study visit, all participants will undergo a medical history review,
fitness testing, body measurements, muscle and fat measurements, blood collection,
echocardiogram, questionnaires to assess quality of life and activity levels, and an
ultrasound of the brachial artery (on the upper arm) and carotid artery (on the neck) to
measure artery size.
Participants in the exercise program will exercise (e.g., walking, running, cycling,
stretching, and weight training) for 1 hour at the study exercise laboratory 2 days a week
for 12 weeks. If participants cannot come to the laboratory, they may exercise at home,
under the guidance of study researchers. Participants will wear a pedometer on select days
and keep an activity log to record how far they walk. At the end of the 12-week program,
participants will undergo repeat baseline testing. They will also receive a written,
personalized exercise program that they can follow on their own. Participants will receive
weekly phone calls from study researchers and will attend study visits once a month for 3
months for follow-up and monitoring. Baseline testing will occur again at the end of the
3-month follow-up period.
Participants in the control group will attend group sessions once a week for 12 weeks at
which time they will watch videos, including some exercise videos, and play games that do
not require physical activity. At the end of Week 12, participants will undergo repeat
baseline testing. They will then have the option of taking part in the exercise program.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|